Pepper Bio
Year2024
RoundSeed
Amount$6.5M
Overall
Summary
20 slides
20 slides
1 slide
Pepper Bio aims to end the era of untreatable diseases.
2 slides
Patients often need luck for effective treatment due to limited and specific medical diagnoses; my personal experience with Alzheimer’s exemplifies the lack of available treatments.
1 slide
Pepper’s team combines scientific rigor and business acumen, with leaders from prestigious institutions and extensive industry experience.
1 slide
The drug discovery industry faces issues such as static studies, biased research, and correlation issues that fail to address causation.
1 slide
Pepper’s transomics approach provides a comprehensive and functional understanding of biology, revealing causal relationships.
4 slides
Pepper's technology exceeds current target ID approaches, addressing key questions in drug development, and integrates seamlessly into existing pharma processes to optimize target and drug selection.
1 slide
Pepper’s platform can be applied to large therapeutic areas—oncology, neurodegenerative, and inflammatory diseases—offering significant market opportunities.
1 slide
Pepper can develop drugs internally for high control and value capture or form partnerships with pharma for early and recurring revenue.
2 slides
Focusing on oncology, specifically three cancers, Pepper projects to reach clinical trials soon, with significant market potential in the US and EU.
3 slides
Pepper has established partnerships generating early revenue and is on a trajectory to significantly increase deal sizes, evidenced by strong traction with leading drug developers.
2 slides
Pepper is leading the shift towards transomics, defining the future of precision medicine and aiming to transform drug discovery by integrating biological understanding.
1 slide
Join Pepper Bio in driving the future of drug discovery and ending untreatable diseases.
